E. coli Nissle 1917
ApprovedSmall molecule
E. coli Nissle 1917 is one of 59 small molecule programs targeting Ulcerative Colitis. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
460 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Velsipity
PfizerPhase 3
Jyseleca
GileadPhase 3
Skyrizi
AbbViePhase 3
Orencia
Bristol-Myers SquibbPhase 3
Mesalazine
FerringPhase 3
Adtralza
LEO PharmaPhase 3
Purinethol
SStason
Phase 3
Afimkibart
RochePhase 3
PTM SEMA
GileadPhase 3
E. coli Nissle 1917
KKangbuk Samsung Hospital
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for E. coli Nissle 1917. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- KKangbuk Samsung Hospital